Promoter holding
64.27%
PB
Panacea Biotec Limited - Due diligence report
A 360° intelligence report on Panacea Biotec: trust score, financial health, credit view, compliance, directors, growth and distress signals…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Panacea Biotec — 360° Intelligence Report
Generated from MCA filings & public records68/100
Trust Score
Moderate
Panacea Biotec is assessed as Moderate with a Trust Score of 68/100. Panacea Biotec is an active public limited indian non-government company incorporated in 1984, operating in the Life Sciences sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 24 Jul 2026 from the latest processed filings. Panacea Biotec Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
60/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
35/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
- Externally credit-rated (D).
Charges position: 1 open (739.69 cr) · 38 satisfied (3,545.32 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 5 | 48.0 cr |
| State Bank Of India | 10 | 48.0 cr |
| Sbicap Trustee Company Limited | 1 | 48.0 cr |
| Idbi Bank Limited | 2 | 48.0 cr |
| Bank Of India | 1 | 48.0 cr |
| Edelweiss Asset Reconstruction Company Limited | 1 | 48.0 cr |
Compliance Score: 60/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (116 disclosure(s)).
- 23 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 35/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| AMBIKA SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARSHET JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MUKUL GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJENDER PAL SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANKESH JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| INDRA KUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajesh Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANDEEP JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATESH SARVASIDDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINOD GOEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEVENDER GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NAROTAM KUMAR JUNEJA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KRISHAN KUMAR JALAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINOD GOEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Sanjay Trehan | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 16 directors on the board.
- INDRA KUMAR SHARMA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 12 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
2
Group entities
4
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Meyten Realtech Private Limited | Subsidiary Company | 74.00% |
| Panacea Biotec (international)sa | Subsidiary Company | 74.00% |
| Panacea Biotec Germany Gmbh | Subsidiary Company | 74.00% |
| Panacea Biotec Pharma Limited | Subsidiary Company | 74.00% |
| Adveta Power Private Limited | Joint Ventures | 74.00% |
| Panera Biotec Private Limited | Associate Company | 74.00% |
Key managerial personnel: HARSHET JAIN (Whole-time director) · ANKESH JAIN (Whole-time director) · SANDEEP JAIN (Managing Director) · VINOD GOEL (CFO) · DEVENDER GUPTA (CFO) · RAJESH JAIN (Managing Director) · Sanjay Trehan (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 80
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 42+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
8 director exits within 2 years.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.03 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 739.69 cr already registered.
- Compliance gaps should be priced into terms.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events16 Dec 2025
Director appointed
VINOD GOEL (CFO)
15 Dec 2025
Director ceased
DEVENDER GUPTA
Director ceased
VINOD GOEL
28 Mar 2025
Director ceased
RAJENDER PAL SINGH
Director ceased
VENKATESH SARVASIDDHI
Director ceased
KRISHAN KUMAR JALAN
14 Feb 2025
Director appointed
HARSHET JAIN (Whole-time director)
Director appointed
RAJENDER PAL SINGH (Director)
Director appointed
VENKATESH SARVASIDDHI (Director)
Director appointed
KRISHAN KUMAR JALAN (Director)
Director appointed
Sanjay Trehan (Whole-time director)
Director ceased
HARSHET JAIN
Director ceased
Sanjay Trehan
25 Dec 2024
Director ceased
Rajesh Jain
13 Nov 2024
Director appointed
Rajesh Jain (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
16 active director(s) / partner(s); review board churn before relying on management continuity.
23 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 2 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of D from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Halewood Laboratories | U24231GJ2000PTC038236 | Ahmedabad, Gujarat, India |
| Kelvin Natural Mint Private Limited | U36999UP2018PTC108645 | Bareilly, Uttar Pradesh, India |
| Klmlab | U24230MH2010PTC251089 | Mumbai, Maharashtra, India |
| Kopl | U85110KA1991PLC012095 | Bangalore, Karnataka, India |
| Hetero Biopharma | U24290TG2016PLC111946 | Balanagar, Telangana, India |
| Skymap | U24233DL2006PTC150088 | New Delhi, Delhi, India |
| Torque Pharmaceuticals | U24119CH1986PTC007151 | Chandigarh, Chandigarh, India |
| Unicure India Ltd | U74899DL1980PLC010642 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Panacea Biotec before audits and certifications: compliance score 60/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Panacea Biotec: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Panacea Biotec - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Panacea Biotec pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Panacea Biotec - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Panacea Biotec an active company?
Panacea Biotec has MCA status “Active” with a compliance score of 60/100 (Moderate).
Is Panacea Biotec financially healthy?
Panacea Biotec has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Panacea Biotec?
Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Panacea Biotec?
Promoters hold a majority stake - exact percentages are in the full report. 16 active director(s) are on record.
Does Panacea Biotec have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 38 earlier charge(s) stand satisfied.
Is Panacea Biotec up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 60/100 (Moderate).
Is it risky to lend to Panacea Biotec?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
